Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet-Reference-Cited by-同舟云学术

Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet

Published:2011-04-15 Issue:7 Volume:25 Page:1168-1173
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Østergaard M,Nyvold C G,Jovanovic J V,Andersen M T,Kairisto V,Morgan Y G,Tobal K,Pallisgaard N,Özbek U,Pfeifer H,Schnittger S,Grubach L,Larsen J K,Grimwade D,Hokland P

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201169.pdf

Reference16 articles.

1. Webb DK . Management of relapsed acute myeloid leukaemia. Br J Haematol 1999; 106: 851–859.

2. Freeman SD, Jovanovic JV, Grimwade D . Development of minimal residual disease-directed therapy in acute myeloid leukemia. Semin Oncol 2008; 35: 388–400.

3. van der Velden VH, Boeckx N, Gonzalez M, Malec M, Barbany G, Lion T et al. Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease--a study within the Europe Against Cancer Program. Leukemia 2004; 18: 884–886.

4. Muller MC, Erben P, Saglio G, Gottardi E, Nyvold CG, Schenk T et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 2008; 22: 96–102.

5. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—a Europe Against Cancer program. Leukemia 2003; 17: 2318–2357.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia;British Journal of Haematology;2020-03-16

2. Clinician-friendly reports of molecular measurable residual disease monitoring in acute promyelocytic leukemia;Annals of Hematology;2019-08-24

3. Quantitative monitoring of minimal residual disease in childhood acute lymphoblastic leukemia usingTEL-AML1fusion transcript as a marker;Pediatric Investigation;2018-12

4. The Prognostic Significance of Measurable (“Minimal”) Residual Disease in Acute Myeloid Leukemia;Current Hematologic Malignancy Reports;2017-10-13

5. Measurable residual disease testing in acute myeloid leukaemia;Leukemia;2017-04-07